Katyayani (Katya) Papatla, MD, MPH
she/her/hers
Assistant Professor of Obstetrics, Gynecology and Reproductive SciencesCards
About
Research
Publications
2026
A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer.
Santin A, Roque D, Siegel E, Ettorre V, Greenman M, McNamara B, Papatla K, Kailasam A, Buza N, Clark M, Hui P, Dottino P, Ratner E, Bellone S. A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer. Clinical Cancer Research 2026, of1-of10. PMID: 42132892, DOI: 10.1158/1078-0432.ccr-26-0144.Peer-Reviewed Original ResearchThis study investigates sacituzumab govitecan, a Trop-2–targeted drug, showing 28% response in recurrent endometrial cancer and manageable safety in heavily pretreated patients.Real World Outcomes of Pembrolizumab and Reduced-Dose Lenvatinib in Recurrent Endometrial Cancer by Platinum and p53 Status
Dzienny A, Abozenah Y, Griffith J, Sohail S, Pan Y, Vlamis C, Yamartino K, Leclair J, Israel G, Greenman M, McNamara B, Azodi M, Ratner E, Santin A, Dottino P, Papatla K, Kailasam A, Hui P, Buza N, Altwerger G. Real World Outcomes of Pembrolizumab and Reduced-Dose Lenvatinib in Recurrent Endometrial Cancer by Platinum and p53 Status. Gynecologic Oncology Reports 2026, 65: 102084. PMID: 42095053, PMCID: PMC13139971, DOI: 10.1016/j.gore.2026.102084.Peer-Reviewed Original Research
2025
Association of platinum-based chemotherapy with survival in ovarian carcinosarcoma: a retrospective 2-center cohort study
Abozenah Y, Erfani H, Haunschild C, Upadhyay A, Greenman M, McNamara B, Papatla K, Clark M, Dottino P, Azodi M, Santin A, Ratner E, Litkouhi B, English D, Altwerger G. Association of platinum-based chemotherapy with survival in ovarian carcinosarcoma: a retrospective 2-center cohort study. International Journal Of Gynecological Cancer 2025, 36: 104440. PMID: 41535186, DOI: 10.1016/j.ijgc.2025.104440.Peer-Reviewed Original ResearchA phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses
Ettorre V, Bellone S, Greenman M, McNamara B, Palmieri L, Sethi N, Demirkiran C, Papatla K, Kailasam A, Siegel E, Ratner E, Santin A. A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses. Gynecologic Oncology 2025, 197: 110-115. PMID: 40334308, DOI: 10.1016/j.ygyno.2025.04.591.Peer-Reviewed Original ResearchPreclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma.
Greenman M, Demirkiran C, Bellone S, Hartwich T, McNamara B, Ettorre V, Santin N, Sethi N, Yang-Hartwich Y, Papatla K, Ratner E, Santin A. Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma. Cancer Research Communications 2025, 5: 774-782. PMID: 40299780, PMCID: PMC12062949, DOI: 10.1158/2767-9764.crc-25-0057.Peer-Reviewed Original Research
2024
Mitigating disparity?: Treatment patterns, survival, and recurrence rates by race, ethnicity, and hospital site across a large urban health system
Papatla K, Orfanelli T, Stoffels G, Layne T, Baldwin E, Leibold A, Blank S, Cohen S. Mitigating disparity?: Treatment patterns, survival, and recurrence rates by race, ethnicity, and hospital site across a large urban health system. Gynecologic Oncology Reports 2024, 53: 101372. PMID: 38584803, PMCID: PMC10997945, DOI: 10.1016/j.gore.2024.101372.Peer-Reviewed Original Research
2022
2022-RA-631-ESGO The impact of COVID 19 on cervical cancer screening and triage
Velasquez J, Papatla K, Kaplowitz E, Coughlin A, Zachem A, Goldberger C, Blank S. 2022-RA-631-ESGO The impact of COVID 19 on cervical cancer screening and triage. International Journal Of Gynecological Cancer 2022, 32: a374-a375. DOI: 10.1136/ijgc-2022-esgo.803.Peer-Reviewed Original Research
2021
COVID-19 and Gynecologic Oncology: What Have We Learned?
Leibold A, Papatla K, Zeligs K, Blank S. COVID-19 and Gynecologic Oncology: What Have We Learned? Current Treatment Options In Oncology 2021, 22: 117. PMID: 34812973, PMCID: PMC8609172, DOI: 10.1007/s11864-021-00905-5.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2019
Second primary anal and oropharyngeal cancers in cervical cancer survivors
Papatla K, Halpern M, Hernandez E, Brown J, Benrubi D, Houck K, Chu C, Rubin S. Second primary anal and oropharyngeal cancers in cervical cancer survivors. American Journal Of Obstetrics And Gynecology 2019, 221: 478.e1-478.e6. PMID: 31128108, DOI: 10.1016/j.ajog.2019.05.025.Peer-Reviewed Original ResearchSecond primary uterine malignancies after radiation therapy for cervical cancer
Papatla K, Houck K, Hernandez E, Chu C, Rubin S. Second primary uterine malignancies after radiation therapy for cervical cancer. Archives Of Gynecology And Obstetrics 2019, 300: 389-394. PMID: 31069490, DOI: 10.1007/s00404-019-05187-9.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Clinical Care
Overview
Katyayani (Katya) Papatla, MD, MPH, is a gynecologic oncologist specializing in cancers of the female reproductive system, including ovarian, uterine, cervical, vulvar, and vaginal cancers.
Dr. Papatla is dedicated to supporting her patients and finds inspiration in their strength and resilience. "It is such a privilege to share this journey with my patients, and I am constantly inspired by their stories," she says.
She advises women to be vigilant about their health, encouraging annual gynecological visits and prompt attention to symptoms such as postmenopausal bleeding, persistent abdominal pain, or unexpected weight loss. "Don't be afraid to listen to your body and see your physician if something feels off,” she says.
Dr. Papatla received her medical degree and a master's in public health from the University of Miami Miller School of Medicine. She completed her residency at Temple University Hospital and a fellowship in gynecologic oncology at the Icahn School of Medicine at Mount Sinai. She is an assistant professor of obstetrics, gynecology and reproductive sciences at Yale School of Medicine.
Clinical Specialties
Gynecology; Minimally Invasive Gynecology
Fact Sheets
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Learn More on Yale MedicineUterine Sarcoma
Learn More on Yale MedicineUterine Cancer
Learn More on Yale Medicine
Board Certifications
Obstetrics & Gynecology
- Certification Organization
- AB of Obstetrics & Gynecology
- Original Certification Date
- 2024
Yale Medicine News
News
News
- July 17, 2026
Women’s Health Research at Yale Funds Projects on Obesity and Ovarian Aging, Diabetes, Cancers, and Autoimmunity
- April 21, 2025
Yale Cancer Center Research Breakthroughs Unveiled at AACR Annual Meeting
- March 20, 2025
Smilow Cancer Hospital Gynecologic Oncology Expertise in Fairfield County
- November 07, 2024
Yale Ob/Gyn Faculty Present the Latest in Gynecologic Oncology at Memorial Conference
Get In Touch
Contacts
Appointment Number
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.